Exelixis (EXEL) Tops Q3 EPS by 5c, Revenue Misses, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures rise on tech buying, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 2, 2021 4:05 PM EDT
- Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Million -
- GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.20 -
- Conference Call and Webcast Today at 5:00 PM Eastern Time -
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Exelixis continued to execute across all facets of our business in the third... More
